Evolving synergistic combinations of targeted immunotherapies to combat cancer
Evolving synergistic combinations of targeted immunotherapies to combat cancer
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Key Points
Clinical trials have validated immuno-oncology as a new pillar of anticancer therapy.
Combinations could involve two (or more) sequential or simultaneous immunotherapies, and/or immunotherapies in combination with conventional cancer therapies.
The programmed cell death protein 1 (PD1)–PD1 ligand 1 (PDL1) axis seems to be the mo...
Alternative Titles
Full title
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1773831778
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1773831778
Other Identifiers
ISSN
1474-175X
E-ISSN
1474-1768
DOI
10.1038/nrc3973
